Within the Food Allergens Allergy Diagnostics market, product types are differentiated by analytical principle and clinical utility. Immunoassay kits, chiefly ELISA and chemiluminescent formats, dominate with the highest adoption due to their quantitative output and scalability; they underpin both clinical and food‑industry workflows. Molecular diagnostics, employing PCR‑based detection of allergen‑specific DNA or RNA, capture a niche yet fast‑growing share as precision medicine expands, offering superior sensitivity for low‑level contaminants. Skin prick test (SPT) reagents remain essential for immediate hypersensitivity assessment, sustaining demand in allergy clinics despite the shift toward in‑vitro methods. Component‑resolved diagnostics (CRD), leveraging purified allergen molecules, deliver detailed sensitization profiles, attracting specialist practitioners and contributing higher per‑test revenue. Each type adds distinct value: immunoassays drive volume, molecular methods enhance specificity, SPT ensures rapid bedside confirmation, and CRD supports personalized therapy, collectively sustaining the market’s diversified revenue base.